Abstracts tagged "Biologics"

Abstract Number: 090 • 2023 Pediatric Rheumatology Symposium
Safety Outcomes of Combined Biologics Use in Pediatric Rheumatology: A Single Center Experience
Angela Chun¹, MaiLan Nguyen¹, Marietta De Guzman² and Andrea Ramirez³, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine, Houston, TX
Background/Purpose: The management of pediatric rheumatic disease has been forever changed by the advent of biologic drugs and the pursuit of targeted therapy. There is…
Abstract Number: 183 • 2020 Pediatric Rheumatology Symposium
Collaboration Between Rheumatology Clinic and Specialty Pharmacy to Positively Impact Patient Experience and Hospital Stewardship
Alaina Linafelter¹, Julia Harris ², Rob Herr ¹, Stephanie Quinn ¹ and Ashley Cooper ³, ¹Children's Mercy Kansas City, Kansas City, Missouri, ²Children's Mercy Kansas City, Overland Park, ³Children's Mercy Kansas City, Kansas City
Background/Purpose: Biologic medications are commonly utilized to treat pediatric rheumatic diseases. Being high-cost, most third-party payors require dispensing through a specialty pharmacy. Common challenges with…
Abstract Number: L12 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study
Evgeniy Nasonov ¹, Saeed Fatenejad ², Elena Korneva ³, Diana Krechikova ⁴, Alexey Maslyansky ⁵, Tatyana Plaksina ⁶, Marina Stanislav ⁷, Rumen Stoilov ⁸, Tamara Tyabut ⁹, Sergey Yakushin ¹⁰, Elena Zonova ¹¹ and Mark Genovese¹², ¹FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, ²SFC Medica, Charlotte, North Carolina, ³R-Pharm, Moscow, Russia, ⁴Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways, Smolensk, Russia, ⁵SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov" of the Ministry of Healthcare of the Russian Federation, St-Petersburg, Russia, ⁶SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", N.Novgorod, Russia, ⁷V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁸UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, ⁹Belarusian Medical Academy of Postgraduate Education, City Clinical Hospital N1, Minsk, Belarus, ¹⁰Ryazan State Medical University, Ryazan, Russia, ¹¹Novosibirsk State Medical University, State Clinical Polyclinic 1, Novosibirsk, Russia, ¹²Stanford University, Stanford, CA
Background/Purpose: Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 1, 2. Here we present the results of the first phase III study of…
Abstract Number: L13 • 2019 ACR/ARP Annual Meeting
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
Philip J. Mease¹, Proton Rahman ², Alice B. Gottlieb ³, Elizabeth Hsia ⁴, Alexa Kollmeier ⁵, Xie Xu ⁶, Ramanand Subramanian ⁵, Prasheen Agarwal ⁵, Shihong Sheng ⁵, Bei Zhou ⁵, Désirée van der Heijde ⁷ and Iain McInnes ⁸, ¹Swedish Medical Center and University of Washington, Seattle, Washington, ²Memorial University of Newfoundland, Newfoundland, Canada, ³Icahn School of Medicine at Mt Sinai, NY, NY, New York, New York, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, Pennsylvania, ⁵Janssen Research & Development, LLC, Spring House, Pennsylvania, ⁶Janssen Research & Development, LLC, Spring House, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved for psoriasis (PsO). We assessed GUS efficacy and safety in DISCOVER-1 (ACR2019 Abstract ID697955) and DISCOVER-2,…
Abstract Number: L17 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial
Eric Morand¹, Richard Furie ², Yoshiya Tanaka ³, Ian Bruce ⁴, Anca Askanase ⁵, Christophe Richez ⁶, Sang-Cheol Bae ⁷, Philip Brohawn ⁸, Lilia Pineda ⁹, Anna Berglind ¹⁰ and Raj Tummala ⁹, ¹Monash University, Melbourne, Victoria, Australia, ²Zucker School of Medicine at Hofstra/Northwell, New York, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁵Columbia University, New York, ⁶CHU de Bordeaux-GH Pellegrin, Bordeaux, France, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁸Former employee of AstraZeneca, Gaithersburg, Maryland, ⁹AstraZeneca, Gaithersburg, Maryland, ¹⁰AstraZeneca, Gothenburg, Sweden
Background/Purpose: Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with…
Abstract Number: 71 • 2019 ACR/ARP Annual Meeting
Inhibition of Nuclear Pore Export Ameliorates Lupus via Modulation of Plasma Cell Generation and Survival
Javier Rangel-Moreno¹, Maria de la luz Garcia-Hernandez ², Teresa Owen ³, Jennifer Barnard ³, Bruce Goldman ³, Christopher Ritchlin ², Douglas Widman ⁴, Savanna Gornisiewicz ⁴, Sharon Tamir ⁴ and Jennifer H Anolik ³, ¹University of Rochester Medical center, Rochester, NY, ²Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ³University of Rochester, Rochester, NY, ⁴Karyopharm Therapeutics, Newton, MA
Background/Purpose: A major challenge in lupus is the elimination of autoreactive plasma cells, which amplify inflammation at peripheral sites via deposition of autoantibody-self antigen complexes.…
Abstract Number: 1522 • 2019 ACR/ARP Annual Meeting
Inflammatory Bowel Disease and Anterior Uveitis in Patients Treated with Ixekizumab for Radiographic Axial Spondyloarthritis: Results from Two Phase 3 Studies Through 52 Weeks
Sergio Schwartzman¹, Atul Deodhar ², Andris Kronbergs ³, Silvia Santisteban ³, Sandra Garces ³, David Sandoval ³, Jeffrey Lisse ³, Fangyi Zhao ³, Denis Poddubnyy ⁴ and James Rosenbaum ⁵, ¹The Hospital for Special Surgery, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY, ²Oregon Health & Science University, Portland, OR, ³Eli Lilly and Company, Indianapolis, IN, ⁴Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁵Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, Portland, OR
Background/Purpose: Radiographic axial spondyloarthritis (r-axSpA) is a chronic inflammatory disease involving the axial skeleton; inflammatory bowel disease (IBD) and acute anterior uveitis (AAU) are common…
Abstract Number: 2665 • 2019 ACR/ARP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica Symptoms Treated with Tocilizumab in Routine Clinical Practice
Sebastian Unizony¹, Robert Spiera ², Jinglan Pei ³, Páris Sidiropoulos ³, Jennie Best ⁴ and John Stone ¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Hospital for Special Surgery, New York, NY, ³Genentech, South San Francisco, CA, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Approximately 50% of patients with giant cell arteritis (GCA) also have polymyalgia rheumatica (PMR) symptoms.1 The purpose of this study was to determine whether…
Abstract Number: 194 • 2019 ACR/ARP Annual Meeting
Predicting Remission in Rheumatoid Arthritis: External Validation for Tocilizumab Monotherapy Using Corrona Real World Data
Fredrik Johansson¹, Jamie Collins ², Sara Gale ³, Hongshu Guan ⁴, Seoyoung C. Kim ⁵, Elena Losina ⁶, David Sontag ¹, Jacklyn Stratton ⁴, Huong Trinh ³, Jeffrey Greenberg ⁷ and Daniel Solomon ⁸, ¹MIT, Cambridge, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, ³Genentech, San Francisco, CA, ⁴Brigham and Women's Hospital, Boston, ⁵Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Corrona, LLC; NYU School of Medicine, Waltham, MA, ⁸Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Predicting remission in rheumatoid arthritis (RA) is an important goal for tailoring therapy. Tocilizumab (TCZ) has been found in randomized controlled trials (RCT) to…
Abstract Number: 1554 • 2019 ACR/ARP Annual Meeting
Effect of Secukinumab on Radiographic Progression Through 2 Years in Patients with Active Psoriatic Arthritis: End-of-study Results from a Phase III Study
Philip Mease¹, Robert B.M. Landewé ², Proton Rahman ³, Hasan Tahir ⁴, Atul Singhal ⁵, Elke Böttcher ⁶, Sandra Navarra ⁷, Aimee Readie ⁸, Shephard Mpofu ⁹, Evie Maria Delicha ⁹, Luminita Pricop ⁸ and Désirée van der Heijde ¹⁰, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Memorial University, Newfoundland, NL, Canada, ⁴Department of Rheumatology, Whipps Cross University Hospital, London, United Kingdom, ⁵Southwest Rheumatology, Dallas, TX, ⁶Rheumazentrum Favoriten, Vienna, Austria, ⁷University of Santo Tomas Hospital, Manila, Philippines, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Secukinumab (SEC) provided sustained efficacy, inhibition of radiographic progression, and stable safety profile over 52 Weeks (Wks) in patients (pts) with psoriatic arthritis (PsA)…
Abstract Number: 2694 • 2019 ACR/ARP Annual Meeting
Inpatient Treatment Variation in New-Onset Systemic Juvenile Idiopathic Arthritis
Rosemary Peterson¹, Rui Xiao ², Hannah Katcoff ¹, Brian Fisher ¹ and Pamela F. Weiss ¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: The effectiveness of IL-1 and IL-6 inhibitors as first-line therapy in patients with new-onset systemic JIA has led to the concept of a “window…
Abstract Number: 217 • 2019 ACR/ARP Annual Meeting
Fibromyalgia and Multiple Switching of Biologics in Spondylarthritis
Ahmed Negm¹, Nasir Elsidig ¹, Ahlam Al Marzooqi ¹, Noura Zamani ¹, Ayesha Hossaini ¹ and Jamal Al Saleh ¹, ¹Rheumatology Department, Dubai Hospital- Dubai Health Authority, Dubai, Dubai, United Arab Emirates
Background/Purpose: Fibromyalgia (FM) is a condition characterized by chronic widespread pain, tender points, fatigue and disturbed sleep rhythm. Some of these symptoms such as fatigue,…
Abstract Number: 1812 • 2019 ACR/ARP Annual Meeting
Delineating Early Response Trajectories to Biologics in Polyarticular Course Juvenile Idiopathic Arthritis
Lily SH Lim¹, Armend Lokku ², Sarah Ringold ³ and Eleanor M. Pullenayegum ⁴, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Toronto, TOronto, ON, Canada, ³Seattle Children's, Seattle, ⁴Child Health Evaluative Sciences, The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
Background/Purpose: Most biologic trials in juvenile idiopathic arthritis (JIA) treat all participants with the biologic under study for 12 to 16 weeks before randomizing responders…
Abstract Number: 2707 • 2019 ACR/ARP Annual Meeting
Improvement in Patient-Reported Outcomes in Patients Aged 2–5 Years with Polyarticular-Course JIA Treated with Subcutaneous Abatacept: 2-Year Results from a Phase III International Study
Hermine Brunner¹, Nikolay Tzaribachev ², Ingrid Louw ³, Jordi Antón ⁴, Diego Viola ⁵, Bernard Lauwerys ⁶, Rubèn J Cuttica ⁷, Pierre Quartier ⁸, Elisabeth Gervais ⁹, Alexandre Belot ¹⁰, Kirsten Minden ¹¹, Thomas Lutz ¹², Rolando Cimaz ¹³, Mahmood M. T. M. Ally ¹⁴, Riana van Zyl ¹⁵, Inmaculada Calvo Penadés ¹⁶, Joe Zhuo ¹⁷, Robert Wong ¹⁸, Marleen Nys ¹⁹, Yedid Elbez ²⁰, Alberto Martini ²¹, Daniel J. Lovell ²² and Nicolino Ruperto ²³, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Panorama Medical Centre, Parow, South Africa, ⁴Hospital Sant Joan de Déu, Barcelona, Spain, ⁵CAICI Institute, Rosario City, Santa Fe State, Argentina, ⁶Rheumatology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, ⁷Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁸Necker Hospital, Paris, France, ⁹CHU de Poitiers, Rheumatology, Poitiers, France, ¹⁰Centre Hospitalier Universitaire de Lyon, Lyon, France, ¹¹German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ¹²Heidelberg University Hospital, Heidelberg, Germany, ¹³Meyer Children's Hospital in Florence, Florence, Italy, ¹⁴University of Pretoria, Pretoria, South Africa, ¹⁵University of the Free State, Bloemfontein, South Africa, ¹⁶Hospital Univ. La Fe, Valencia, Spain, ¹⁷Bristol-Myers Squibb, Princeton, NJ, ¹⁸Bristol-Myers Squibb, Princeton, ¹⁹Bristol-Myers Squibb, Braine L’Alleud, Belgium, ²⁰Excelya, Boulogne-Billancourt, France, ²¹IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ²²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ²³Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy
Background/Purpose: Efficacy of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label, Phase III international study (NCT01844518).1 Pediatric patient-reported outcomes…
Abstract Number: 249 • 2019 ACR/ARP Annual Meeting
Evaluation of Real-World Early-Line Abatacept versus Tumor Necrosis Factor Inhibitors Persistence in Rheumatoid Arthritis Patients with Anti-Citrullinated Protein Antibody or Rheumatoid Factor Positivity
Damemarie Paul ¹, Xue Han², Irina Yermilov ³, Sarah Gibbs ³ and Michael Broder ³, ¹Bristol-Myers Squibb, Lawrenceville, NJ, ²Bristol-Myers Squibb Company, Princeton, NJ, ³Partnership for Health Analytic Research, LLC, Beverly Hills, CA
Background/Purpose: Abatacept is recommended as first-line biologic therapy in adult patients with moderate to severe RA. We aimed to assess real-world 1-year treatment persistence in…

1
2
3
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].